SR ONE CAPITAL MANAGEMENT, LP Long-Term Concentrated

Location: Redwood City, CA

CIK: 0001910264 · Show all filings

Period: Q1 2025 (← Previous) (Next →)

Filing Date: May 13, 2025

Total Value: $389M (100.0% shares, 0.0% debt)

Holdings (12)

ACLX Arcellx, Inc. 39.5%

Value $154M Shares 2,346,630 Est. Cost $16.72 Unrealized +305.2%

SPRY ARS Pharmaceuticals, Inc. 13.0%

Value $50.48M Shares 4,012,903 Est. Cost $6.79 Unrealized +77.3%

MLYS Mineralys Therapeutics Inc. 12.8%

Value $49.67M Shares 3,127,933 Est. Cost $14.62 Unrealized -21.3%

ZBIO Zenas BioPharma, Inc 10.0%

Value $38.8M Shares 4,911,539 Est. Cost $17.98 Unrealized -56.5%

CRSP CRISPR Therapeutics AG 9.2%

Value $35.7M Shares 1,048,951 Est. Cost $71.59 Unrealized -40.8%

DSGN Design Therapeutics, Inc. 6.5%

Value $25.19M Shares 6,526,476 Est. Cost $16.67 Unrealized -71.4%

ALMS Alumis Inc. 3.1%

Value $12.03M Shares 1,959,896 Est. Cost $13.30 Unrealized -56.3%

OCS Oculis Holding AG 1.6%

Value $6.137M Shares 322,500 Est. Cost $20.50 Unrealized 0.0%

NKTX Nkarta, Inc. 1.6%

Value $6.133M Shares 3,333,333 Est. Cost $11.49 Unrealized -82.2%

ORKA Oruka Therapeutics, Inc 1.1%

Value $4.415M Shares 430,330 Est. Cost $33.46 Unrealized -62.7%

KALA KALA Bio, Inc. 0.9%

Value $3.432M Shares 598,940 Est. Cost $6.53 Unrealized +15.9%

ENGN enGene Holdings Inc. 0.9%

Value $3.35M Shares 747,750 Est. Cost $11.04 Unrealized -43.8%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
ACLX	Arcellx, Inc.	2,346,630	$154M	39.5%	$16.72	+305.2%	Common Stock	03940C100
SPRY	ARS Pharmaceuticals, Inc.	4,012,903	$50.48M	13.0%	$6.79	+77.3%	Common Stock	82835W108
MLYS	Mineralys Therapeutics Inc.	3,127,933	$49.67M	12.8%	$14.62	-21.3%	Common Stock	603170101
ZBIO	Zenas BioPharma, Inc	4,911,539	$38.8M	10.0%	$17.98	-56.5%	Common Stock	98937L105
CRSP	CRISPR Therapeutics AG	1,048,951	$35.7M	9.2%	$71.59	-40.8%	Common Shares	H17182108
DSGN	Design Therapeutics, Inc.	6,526,476	$25.19M	6.5%	$16.67	-71.4%	Common Stock	25056L103
ALMS	Alumis Inc.	1,959,896	$12.03M	3.1%	$13.30	-56.3%	Common Stock	022307102
OCS	Oculis Holding AG	322,500	$6.137M	1.6%	$20.50	0.0%	Ordinary Shares	H5870P102
NKTX	Nkarta, Inc.	3,333,333	$6.133M	1.6%	$11.49	-82.2%	Common Stock	65487U108
ORKA	Oruka Therapeutics, Inc	430,330	$4.415M	1.1%	$33.46	-62.7%	Common Stock	687604108
KALA	KALA Bio, Inc.	598,940	$3.432M	0.9%	$6.53	+15.9%	Common Stock	483119202
ENGN	enGene Holdings Inc.	747,750	$3.35M	0.9%	$11.04	-43.8%	Common Shares	29286M105